Introduction {#Sec1}
============

Acute sore throat (pharyngitis) is one of the most common illnesses for which children and their parents visit primary care physicians \[[@CR1]\]. For example, in the ambulatory setting, acute pharyngitis accounts for around 1 % of primary care visits \[[@CR2]\]. Most cases (up to 80 %) are caused by viruses and are benign and self-limiting \[[@CR3]\]. However, bacteria (e.g. group A beta-hemolytic streptococci) are another common cause, particularly among children \[[@CR4]\].

The diagnosis of pharyngitis must distinguish children with viral pharyngitis, who would not benefit from antibiotic therapy, from those children with group A beta-hemolytic streptococcal pharyngitis, for whom antibiotics are appropriate \[[@CR1]\]. Making this distinction is crucial in attempting to minimize the unnecessary use of antimicrobial agents in children and providing suitable symptomatic relief. The absence of fever or the presence of clinical features such as conjunctivitis, cough, or hoarseness, suggest a viral etiology \[[@CR1]\].

The clinical manifestations of acute sore throat are related to inflammation of the pharynx and/or tonsils, and include pain, redness, heat, and swelling \[[@CR5], [@CR6]\]. Despite the fact that antibiotics are still often requested and prescribed for acute sore throat, many patients (adults and children) consult their primary care physician to establish the cause of the symptoms, to obtain pain relief, and for information on the course of the disease \[[@CR7], [@CR8]\]. Furthermore, because the majority of sore throats are caused by viruses and not bacteria, antibiotics are generally ineffective and not recommended by clinical bodies for primary treatment of sore throat \[[@CR9]\]. Instead, clinically proven over-the-counter (OTC) medications, which provide rapid and effective relief of symptoms of acute sore throat, regardless of cause, are increasingly important in the self-management of this condition.

Throat lozenges containing amylmetacresol (AMC) and 2,4-dichlorobenzyl alcohol (DCBA), which possess antibacterial, antiviral, and local anesthetic properties, provide symptomatic relief of sore throat \[[@CR6], [@CR10]\]. They are licensed for OTC use in the UK and around the world for adults and children for the symptomatic relief of mouth and throat infections \[[@CR11]\]. Safety profiles are well established, and in some countries the lozenges have been used for over 50 years.

Lozenges containing AMC/DCBA have been studied in several clinical trials conducted in adults and have demonstrated significant analgesic, functional, sensorial, and psychological effects from as early as 1--5 minutes and lasting up to 2 h post-dose \[[@CR5], [@CR12], [@CR13]\]. For example, studies have shown that patients taking AMC/DCBA throat lozenges reported experiencing relief from their throat soreness and sore throat pain but also soothing and coating effects \[[@CR5], [@CR14]\]. These lozenges have also been shown to be effective for the symptomatic treatment of sore throat in children aged \>5 years with acute and aggravated chronic pharyngitis \[[@CR15]\].

A primary consideration for the development of a pediatric formulation is the acceptability to children \[[@CR16]\]. Many investigators cite palatability as an important factor in medication adherence and completion of therapy in children, although formal studies are lacking \[[@CR17]\]. Little direct evidence exists to show that poor palatability decreases adherence; however, it is not unreasonable to assume that a more palatable medication is easier to administer to infants and young children. Previous taste testing in children has shown that they generally prefer sweet preparations with fruit flavors \[[@CR18]\]. National favorites are bubble gum and grape in the USA, citrus and red berries in Europe, and liquorice in Scandinavia \[[@CR16]\].

The hedonic facial scale, which uses a pictorial scale of facial expressions, has been commonly employed in determining the acceptability of medications to children \[[@CR18]\]. Compared with spontaneous verbal judgment, this method has the advantage of being more standardized. Studies have shown that children aged as young as 4 years can understand and use this scale to indicate whether a substance tastes pleasant and is therefore acceptable \[[@CR18]\]. This scale has previously been used to evaluate the acceptability of a wide range of medications among children, including steroid preparations \[[@CR19]\], antibiotics \[[@CR20]--[@CR22]\], calcium and vitamin D~3~ \[[@CR23], [@CR24]\], ondansetron \[[@CR25]\], and lansoprazole \[[@CR26], [@CR27]\].

The purpose of this study was to evaluate the acceptability of two licensed, commercially available throat lozenges containing AMC/DCBA, one strawberry and the other orange flavored, in healthy children aged 6--12 years, taken sequentially on the taste-testing day. Taste was assessed using the 7-point hedonic facial score, which was the primary measure of acceptability, as well as spontaneous reaction and verbal responses to questions relating to palatability, flavor, and the feel of the lozenge in the mouth.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was an open-label, single-dose, crossover, taste-testing study in children to investigate the acceptability of two different flavors of AMC/DCBA lozenges. It was conducted in accordance with the Declaration of Helsinki \[[@CR28]\] and was reviewed by the Reading Independent Ethics Committee (Reading, Berkshire, UK). The International Standard Randomized Controlled Trial Number is ISRCTN34958871.

As this study was designed to assess the acceptability of the two lozenge flavors in absolute rather than comparative terms, blinding was not considered necessary given that flavor acceptability, as opposed to efficacy, was the parameter of interest and would have been difficult to achieve as the products taste different.

The subject population comprised healthy children aged 6--12 years, the age range of the target population. Although no formal sample size calculation was performed, 100 children tasting both samples were believed to be an appropriate sample number to evaluate. It was estimated that 120 subjects would need to be screened in order to achieve this.

Subject Selection {#Sec4}
-----------------

Healthy males and females (aged 6--12 years) were recruited from a clinical trial company's database and via advertisements over a 3.5-week period. Parents provided written informed consent for the participation of their child in the study, and the child voluntarily wrote or marked their name on the assent form. Subjects were screened either before or on the day of taste testing, and details of any relevant medical history, medication, and demographics were recorded.

Subjects were excluded if they had a history of hereditary fructose intolerance; sensitivity to an analgesic medication, its ingredients or related products; or any previous history of allergy or known intolerance to AMC, DCBA, or any colouring, flavoring, preservative, sweetener, or surfactant. Other exclusion criteria were a history of hepatic or renal impairment, cardiac disease, high blood pressure, asthma, gastrointestinal disorders, respiratory infection, or any other condition that could have affected the subjects' perception of taste. Subjects were also excluded from enrolment on the taste-testing day if they had taken prescription medications during the previous 7 days, used analgesics or anesthetics, consumed food or drink that may have affected their perception of taste (e.g. highly spiced meals or mint- or menthol-based products) on the testing day, or used non-prescription medication within 4 h prior to taste testing. Other restrictions on the taste-testing day were the presence of a mouth ulcer or dental work carried out on that day. The taste-testing day was to be rescheduled for subjects who met any one of these restriction criteria.

Treatments {#Sec5}
----------

Before receiving a lozenge, each subject cleansed their palate with water and water biscuits. The subjects received a single strawberry-flavored, sugar-free AMC/DCBA lozenge (Strepsils^®^ strawberry sugar free, Reckitt Benckiser Healthcare Limited, Nottingham, UK; PL 00063/0395) followed at least 15 minutes later by a single orange-flavored, colour-free AMC/DCBA lozenge (Strepsils^®^ orange with vitamin C, Reckitt Benckiser Healthcare Limited, Nottingham, UK; PL 016242152). Each lozenge was sucked for 1 minute and then expelled. Both lozenges contained 0.6 mg AMC and 1.2 mg DCBA. In addition, the orange-flavored colour-free lozenge contained 100 mg vitamin C as sodium ascorbate/ascorbic acid. Questions relating to the lozenges' palatability were then asked after each lozenge was spat out.

During protocol development, there were concerns that if the orange-flavored lozenge was tasted first, the strong orange and menthol flavor might affect the subsequent perception of the strawberry flavor, even after the required 15-minute interval and cleansing of the palate. Therefore, the strawberry-flavored lozenge was tasted first by all subjects. This was deemed acceptable given that the purpose of the study was to assess the acceptability of each flavor and not to compare the acceptability of the two flavors. The 15-minutes period between tasting the samples was considered appropriate in terms of maximizing subject compliance. A previous study has shown that complete lozenge dissolution takes approximately 6.77 minutes \[[@CR29]\]. As the children in this study were only required to suck each lozenge for 1 minutes, they were not exposed to more than a standard dose (AMC 0.0022 mg/mL \[standard deviation (SD) 0.0012\] and DCBA 0.0097 mg/mL \[SD 0.0040\]).

Acceptability Assessments and Endpoints {#Sec6}
---------------------------------------

Assessments on the taste-testing day were designed to evaluate the acceptability of both flavors to the children. During the taste-testing session, children were first asked what they would like their medication to taste of. Subjects were asked to indicate their liking for each lozenge, using a 7-point hedonic facial scale (Fig. [1](#Fig1){ref-type="fig"}), which included the following scores: 1 = super bad; 2 = really bad; 3 = bad; 4 = may be good/may be bad; 5 = good; 6 = really good; 7 = super good. After expelling the lozenge, the subjects were asked a series of questions relating to the taste and feel of the lozenge in the mouth and throat.Fig. 1The 7-point hedonic facial scale for assessment of acceptability \[[@CR16]\]

The primary endpoint was the percentage of children who rated each lozenge with a score of \>4 on the 7-point hedonic facial scale, together with descriptive summary statistics (mean, SD, median, minimum, maximum) of the hedonic facial scale scores.

Secondary endpoints included the observed spontaneous reaction to putting the lozenge in the subject's mouth (based on whether the subjects sucked the lozenge for 1 minute or spat it out), the flavor perceived by the subjects in response to the question "What does the medicine taste of?", and the subjects' responses to a series of questions about what they liked and disliked about the taste.

No efficacy assessments were conducted in this study. Assessment of safety included analysis of any adverse events (AEs) spontaneously mentioned by the subjects after they had received each flavor of lozenge.

Statistical Methods {#Sec7}
-------------------

For the primary endpoint, the proportion of subjects who had a hedonic facial score of \>4 (i.e., 5--7) was presented together with the 95 % confidence interval (CI), for each lozenge. For the secondary endpoints, descriptive summary statistics of the hedonic facial scale score for each lozenge were presented together with the 95 % CI for the mean score. The number of times the sample was retained for 1 minute/spat out and responses to questions relating to taste were presented in the listings and summarized descriptively.

Results {#Sec8}
=======

A total of 108 subjects were screened, of whom 103 were eligible and entered the study (59 males; 44 females), with a mean age of 9 years (range 6--12 years). Medical history was reported for 19 subjects. One subject withdrew before tasting the first sample. A total of 102 subjects completed the study, tasting both samples, and were included in the analyses.

Acceptability Analyses {#Sec9}
----------------------

In response to the question "If you could choose the taste of your medicine, what would it taste of?", 44 % of subjects indicated their preference would be strawberry/strawberries, 11 % chocolate, and 7 % orange. For the primary endpoint, 85.3 % of subjects rated the strawberry lozenge with a score of \>4 and 49.0 % rated the orange-flavored lozenge with a score of \>4 (*p* \< 0.0001) (Table [1](#Tab1){ref-type="table"}). The mean (SD) score was 5.72 (1) for the strawberry-flavored lozenge and 4.35 (2) for the orange-flavored lozenge (Table [2](#Tab2){ref-type="table"}).Table 1Proportion of subjects selecting each score on a 7-point hedonic facial scale (primary endpoint)Percentage of subjects selecting each score^a^Strawberry-flavored lozenge (*n* = 102)Orange-flavored lozenge (*n* = 102)Score 1: Super bad2.09.8 2: Really bad1.05.9 3: Bad1.012.7 4: May be good/may be bad10.822.5 5: Good17.622.5 6: Really good40.212.7 7: Super good27.513.7Percentage \[95 % CI\] of subjects selecting a score \>485.3 \[74.8--92.2\]49.0 \[39.3--58.7\]*p* value for difference between treatments\<0.0001^a^Numbers may not total 100 %, because of rounding*CI* confidence intervalTable 2Descriptive summary statistics of the 7-point hedonic facial scale for all subjects (primary endpoint)Hedonic facial scale scoreStrawberry-flavored lozenge (*n* = 102)Orange-flavored lozenge (*n* = 102)Mean scores in different age groups 6 years \[*n* = 13\]6.154.62 7 years \[*n* = 6\]5.334.33 8 years \[*n* = 16\]^a^5.603.93 9 years \[*n* = 20\]5.753.90 10 years \[*n* = 15\]5.204.87 11 years \[*n* = 14\]6.074.71 12 years \[*n* = 19\]5.744.32Overall scores Mean5.724.35 Median64 Maximum77 Minimum11 SD12 SEM0.120.18 UCL65 LCL54^a^One subject withdrew from the study before tasting either lozenge*SD* standard deviation, *SEM* standard error of the mean, *UCL* upper confidence limit, *LCL* lower confidence limit

No subject spontaneously rejected either lozenge or spat it out before being required to do so. When asked directly, the proportion of subjects who had wanted to take the lozenge out of their mouth was 17 % for the strawberry flavor and 46 % for the orange flavor. The proportion of these subjects who wanted to remove the lozenge and who also rated the lozenges as 'super bad'/'really bad', or 'bad' was 4 % for strawberry and 26.5 % for orange. The proportion of subjects answering "yes" to the question "Would you be happy to take it again?" was 94 % for the strawberry lozenge and 56 % for the orange lozenge. The most common reason for not wishing to take the orange lozenge again was that it tasted "sour" (13 % of subjects). The proportion of subjects answering "yes" to the question "Would you be happy for Mum or Dad to give you this flavor medicine when you get a sore throat?" was 86 % for the strawberry-flavored lozenge and 55 % for the orange-flavored lozenge. When asked the specific question "Did your mouth feel soothed?", a high proportion of subjects taking either the strawberry (87 %) or orange (67 %) lozenge reported that their throat had been soothed by the lozenge.

When the subjects were asked how the medicine had made their throat feel, their responses were broadly similar for both lozenges; the proportion of subjects whose throat felt "normal", whose throat felt "not different", or who did not know was 41 and 32 % for the strawberry- and orange-flavored lozenges, respectively (Table [3](#Tab3){ref-type="table"}). These results were expected, as the study was conducted in healthy volunteers.Table 3Subjects' responses to the questions "How did it make your mouth feel?" and "How did it make your throat feel?"CommentPercentage of subjects selecting each scoreMouthThroatStrawberry-flavored lozenge (*n* = 102)Orange-flavored lozenge (*n* = 102)Strawberry-flavored lozenge (*n* = 102)Orange-flavored lozenge (*n* = 102)Normal/not different/don't know3664132Generally positive1992619Smooth/soothed/soft/calm531614Tingly/numb1724612Generally negative41446Hot312NRNR*NR* not reported

No AEs were reported in this study, which is in accordance with the well-established safety profile of AMC/DCBA lozenges.

Discussion {#Sec10}
==========

The palatability of medications, particularly those taken orally, is an important factor in determining medication adherence and completion of drug therapy in young children, and should be an important part in the development process of new pediatric formulations \[[@CR16]\]. This taste-testing study was based on well-recognised and accepted techniques for evaluating the taste of pediatric formulations \[[@CR30], [@CR31]\] and, based on the results of this study, would seem to be applicable to lozenge formulations.

In this study, a high proportion (85.3 %) of the children rated the strawberry-flavored lozenge as tasting 'good', 'really good', or 'super good'. These results are consistent with those of other studies of strawberry-flavored medications in children. For example, in an assessment of antibiotics, Angelilli et al. \[[@CR22]\] found that a strawberry-flavored cefixime preparation was most commonly rated as the best tasting when compared with cherry-, bubble gum- and banana-flavored preparations in children aged 5--8 years. In a further study, strawberry-flavored lansoprazole suspension and tablets were preferred by over 90 % of children (5--11 years), compared with peppermint-flavored ranitidine syrup \[[@CR26], [@CR27]\]. In another study, significantly more children (aged 3--12 years) preferred strawberry-flavored ondansetron syrup to grape-flavored syrup \[[@CR25]\].

However, one strawberry flavor or other flavor may taste quite different to another, depending on the flavor supplier, the medicinal format of the product containing the flavor, or other ingredients with a taste within the formulation, such as the active ingredients. We demonstrated that these particular flavors in AMC/DCBA lozenges were liked by a majority of children within this study.

A previous study conducted in children aged 4--7 years found that sweetness was the most important flavor characteristic for a medication, together with the effective masking of any bitter taste of the active ingredients \[[@CR32]\]. In addition, red fruit (strawberry/raspberry) flavor was found to be the most acceptable to children and although the majority readily accepted citrus flavors, they did not prefer them. Citrus flavor was preferred to banana flavor by fewer children when compared with formulations containing calcium and vitamin D~3~ \[[@CR24]\]. Therefore, in our study, the sourness of the flavor may have been a factor, with the lower absolute palatability of the orange-flavored lozenge being in line with the major dislike reported in this study.

The open-label, uncontrolled design of the study was appropriate given that the objective was to investigate absolute rather than comparative acceptability of the samples. The order in which the samples were tasted was not randomized because of the possibility that the menthol in the orange-flavored lozenge could carry over and affect the taste of the strawberry-flavored lozenge, as menthol in lozenges has been demonstrated to exert effects that are still experienced 30 minutes after consumption \[[@CR33]\]. Therefore, the strawberry-flavored lozenge was taken before the orange-flavored lozenge.

A potential limitation of this study is that it was conducted in healthy children, and thus the results may not necessarily be translated directly to children with acute sore throat, whose perceptions of flavor may be affected by symptoms of a cold \[[@CR34]\]. However, since the main purpose of this study was to evaluate the general acceptability of the two flavored lozenges in absolute rather than comparative terms, and the impact of symptoms of a cold on perception of flavor may differ between subjects, the inclusion of healthy children in this study is considered reasonable. Future work may be warranted involving children with symptoms of upper respiratory tract infection/sore throat.

It is also possible that the order in which the lozenges were tasted (strawberry then orange) had a bearing on the vocabulary used in the responses given to the question asking what the subjects disliked about the flavor. After being asked general questions about what they liked/disliked about the strawberry lozenge, subjects were then asked more specific questions such as "Do you think it tasted sour \[like a lemon\]?". The subjects then tasted the orange-flavored lozenge and were asked the same questions in the same order. Therefore, when subjects were voluntarily describing the taste of the strawberry-flavored lozenge, they had not yet been presented with the words "sour" or "lemon", but when they were describing the orange-flavored lozenge, they had already been given the association of "sour" and "lemon".

Conclusions {#Sec11}
===========

Strawberry-flavored sugar-free AMC/DCBA lozenges were liked by, and acceptable to, the majority of the children in this study; this flavor preference is in line with previous children's medicine studies in Europe. Orange-flavored colour-free AMC/DCBA lozenges with vitamin C were liked by, and acceptable to, approximately half of the children, and older children (10--12 years) found them more acceptable than 6- to 10-year-olds did. Overall, both strawberry and orange would be suitable flavors for lozenges intended for children when they suffer from sore throat.
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